IN2012DN00549A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00549A IN2012DN00549A IN549DEN2012A IN2012DN00549A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A IN 549DEN2012 A IN549DEN2012 A IN 549DEN2012A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A
- Authority
- IN
- India
- Prior art keywords
- subject
- activity
- relates
- compounds
- hif levels
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910089274 | 2009-07-15 | ||
| PCT/CN2010/001057 WO2011006355A1 (en) | 2009-07-15 | 2010-07-14 | Compounds as hypoxia mimetics, and compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00549A true IN2012DN00549A (enExample) | 2015-06-12 |
Family
ID=43448908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN549DEN2012 IN2012DN00549A (enExample) | 2009-07-15 | 2010-07-14 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8742138B2 (enExample) |
| EP (1) | EP2454249B1 (enExample) |
| JP (1) | JP5847710B2 (enExample) |
| KR (1) | KR20120065311A (enExample) |
| CN (1) | CN102164905B (enExample) |
| AU (1) | AU2010273101B2 (enExample) |
| CA (1) | CA2767911C (enExample) |
| ES (1) | ES2702524T3 (enExample) |
| IL (1) | IL217531A0 (enExample) |
| IN (1) | IN2012DN00549A (enExample) |
| SG (1) | SG177598A1 (enExample) |
| WO (1) | WO2011006355A1 (enExample) |
| ZA (1) | ZA201200293B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2606631T3 (es) | 2011-07-22 | 2017-03-24 | Beijing Betta Pharmaceuticals Co., Ltd | Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos |
| JP2014523917A (ja) * | 2011-07-29 | 2014-09-18 | ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド | 低酸素模倣剤としての化合物の安定な多形体、およびその使用 |
| CN105384687B (zh) | 2014-09-02 | 2018-05-01 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| US20160193238A1 (en) * | 2015-01-05 | 2016-07-07 | National Cancer Center | HNF4-alpha ANTAGONIST AND USE THEREOF |
| CN113694077A (zh) * | 2015-08-13 | 2021-11-26 | 索马根尼科斯公司 | 用于伤口愈合的短小发夹rna与微rna的组合物以及方法 |
| AU2018264313B2 (en) | 2017-05-09 | 2020-06-04 | Kind Pharmaceutical | Indolizine derivatives and application thereof in medicine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003228348A1 (en) * | 2002-03-20 | 2003-10-08 | John T. Fassett | Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors |
| CA2618770A1 (en) * | 2005-08-25 | 2007-03-01 | Emory University | Hif inhibitors |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| CA2634168C (en) | 2005-12-09 | 2013-04-23 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| TW200808793A (en) * | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| PL2134720T3 (pl) * | 2007-03-29 | 2011-04-29 | Novartis Ag | Heterocykliczne spiro-związki |
| US8324405B2 (en) * | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| EP2341904A1 (en) * | 2008-08-26 | 2011-07-13 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
-
2010
- 2010-07-14 IN IN549DEN2012 patent/IN2012DN00549A/en unknown
- 2010-07-14 AU AU2010273101A patent/AU2010273101B2/en not_active Ceased
- 2010-07-14 ES ES10799353T patent/ES2702524T3/es active Active
- 2010-07-14 KR KR1020127001420A patent/KR20120065311A/ko not_active Ceased
- 2010-07-14 CN CN201080002367.7A patent/CN102164905B/zh not_active Expired - Fee Related
- 2010-07-14 WO PCT/CN2010/001057 patent/WO2011006355A1/en not_active Ceased
- 2010-07-14 JP JP2012519871A patent/JP5847710B2/ja not_active Expired - Fee Related
- 2010-07-14 US US13/384,097 patent/US8742138B2/en active Active
- 2010-07-14 CA CA2767911A patent/CA2767911C/en not_active Expired - Fee Related
- 2010-07-14 EP EP10799353.7A patent/EP2454249B1/en not_active Not-in-force
- 2010-07-14 SG SG2012001806A patent/SG177598A1/en unknown
-
2012
- 2012-01-12 IL IL217531A patent/IL217531A0/en unknown
- 2012-01-13 ZA ZA2012/00293A patent/ZA201200293B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2767911A1 (en) | 2011-01-20 |
| CA2767911C (en) | 2016-03-29 |
| HK1161234A1 (en) | 2012-08-24 |
| EP2454249A1 (en) | 2012-05-23 |
| JP5847710B2 (ja) | 2016-01-27 |
| CN102164905B (zh) | 2014-04-30 |
| EP2454249A4 (en) | 2012-12-12 |
| IL217531A0 (en) | 2012-02-29 |
| CN102164905A (zh) | 2011-08-24 |
| ZA201200293B (en) | 2012-09-26 |
| US8742138B2 (en) | 2014-06-03 |
| AU2010273101B2 (en) | 2016-02-25 |
| WO2011006355A1 (en) | 2011-01-20 |
| KR20120065311A (ko) | 2012-06-20 |
| AU2010273101A2 (en) | 2012-03-15 |
| EP2454249B1 (en) | 2018-09-19 |
| AU2010273101A1 (en) | 2012-02-02 |
| JP2012532897A (ja) | 2012-12-20 |
| SG177598A1 (en) | 2012-02-28 |
| US20120172399A1 (en) | 2012-07-05 |
| ES2702524T3 (es) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00624A (enExample) | ||
| IN2014DN09782A (enExample) | ||
| IN2015DN00438A (enExample) | ||
| MX2015003048A (es) | Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado. | |
| IN2014DN05986A (enExample) | ||
| PH12014500075A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| WO2011091366A3 (en) | Methods of treating or preventing periodontitis and diseases associated with periodontitis | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| UA116196C2 (uk) | Синтетичний міметик апеліну для лікування серцевої недостатності | |
| EP2294184A4 (en) | TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY | |
| JO3300B1 (ar) | مركبات وتركيبات لتعديل نشاط egfr | |
| GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| EA201390704A1 (ru) | Соединения, ингибирующие металлоферменты | |
| GB2482817A (en) | Novel use | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| IN2012DN00549A (enExample) | ||
| EP2585067A4 (en) | COMPOUND FOR THE TREATMENT OF ENTEROVIRUS | |
| MY173722A (en) | Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| EA201390876A1 (ru) | Соединения, ингибирующие металлоферменты | |
| MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation | |
| MX2010004814A (es) | Metodos para tratar esclerodermia. | |
| WO2010117727A3 (en) | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions | |
| NZ705406A (en) | Use of attenuated strains of toxoplasma for the prevention or treatment of cryptosporidiosis |